Crestor European Label Changes Prompt FDA Public Health Advisory; Safety Review Ongoing

FDA is using European label update as an opportunity to remind physicians of three "key safety messages" contained in Crestor's U.S. label. FDA is not recommending changes to the U.S. label, pending an evaluation of postmarketing reports of rhabdomyolysis.